

Recombinant Human Kallikrein 2/KLK2 Protein (His Tag)

Catalog Number: PKSH032666

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Species	Human
Source	HEK293 Cells-derived Human Kallikrein 2;KLK2 protein Pro19-Pro261, with an C-terminal His
Calculated MW	27.9 kDa
Observed MW	10-12&16-19&28-33 kDa
Accession	P20151
Bio-activity	Not validated for activity

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Concentration	Subject to label value.
Endotoxin	< 0.01 EU per µg of the protein as determined by the LAL method.
Storage	Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping	This product is provided as liquid. It is shipped at frozen temperature with blue ice/ gel packs. Upon receipt, store it immediately at < - 20°C.
Formulation	Supplied as a 0.2 µm filtered solution of 20mM Acetate, 250mM Trehalose, 0.02% Tween 80, pH5.0.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Kallikrein-2 (KLK2) is a secreted serine protease that belongs to the peptidase S1 family of Kallikrein subfamily. KLK2 contains 1 peptidase S1 domain. It is highly expressed in the human prostate gland. KLK2 can cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin, but Preferential cleavages of Arg-|-Xaa bonds in small molecule substrates. It also highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Me t-|-Xaa or Leu-|-Xaa. KLK2 is inhibited by serpins such as protein C inhibitor, antichymotrypsin, and plasminogen. KLK2 is considered to be a biomarker for prostate cancer.

For Research Use Only